Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

To mimic physiological insulin release, both long-acting and short-acting insulin ... we introduced the world’s first pen-shaped devices for subcutaneous injection in 1985.

don't realise reusable pens are both safe and easy to use, and often work out cheaper for the NHS in the long run. "My mission is to ensure people who need to use insulin, and healthcare workers ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

Advantages of using insulin pens Long-acting insulin analogues offer several benefits over traditional human insulin. They ...

Some Medicare plans may cover Basaglar, but it varies by plan. Learn which plans cover Basaglar, how to find coverage, and what you can expect to pay.